Trial · NCT03168256
CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
NCT03168256, Phase 3, Completed, Can-Fite BioPharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis. Trials, record NCT03168256. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03168256
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
- NCT number
- NCT03168256
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 528 participants, actual
- Lead sponsor
- Can-Fite BioPharma
- Conditions
- Plaque Psoriasis
- Interventions
- CF101 2mg, CF101 3mg, Apremilast 30mg, Placebo Oral Tablet
- First posted
- 2017-05-30
- Last updated
- 2022-06-28
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) at Week 16 | 16 weeks | Evaluate the efficacy of oral CF101 2 mg or 3 mg twice daily (BID) in patients with moderate-to-severe plaque psoriasis, compared with placebo, as determined by the proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) at Week 16 (superiority) |
| Primary | Adverse event profile in this patient popluation | 16 weeks | Nature, incidence and severity of treatment-emergent adverse events |
| Secondary | Psoriasis Area and Severity Index (PASI) score response of ≥50% (PASI 50) at Week 16 | 16 weeks | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve PASI 50 at Week 16 (superiority); |
| Secondary | Physician Global Assessment (PGA) | 16 weeks | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve PGA score of 0 or 1 at Week 16; |
| Secondary | Psoriasis Disability Index (PDI) | 16 weeks | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve improvement on the PDI at Week 16; |
| Secondary | CF101 PASI 75 compare to apremilast | weeks 16-32 | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PASI 75 at Weeks 16 and 32; |
| Secondary | CF101 PGA score compare to apremilast | weeks 16-32 | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PGA score of 0 or 1, at Weeks 16 and 32; |
| Secondary | CF101 PASI 50 compare to apremilast | weeks 16-32 | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PASI 50 at Weeks 16 and 32; |
| Secondary | CF101 PDI improvement compare to apremilast | weeks 16-32 | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve an improvement in PDI at Weeks 16 and 32; |
| Secondary | Apremilast PASI 75 compare to placebo | weeks 16-32 | Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PASI 75, PGA score of 0 or 1, PASI 50, and improvement in PDI at Week 16 (superiority); |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38279575 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03168256
GET https://conductscience.org/api/trials/v1/NCT03168256/registered